Commentary

Video

Unpacking Regenerative Medicines and Start-Up Funding with Luis Alvarez

Author(s):

Grant Playter

Luis Alvarez, PhD, founder of Theradaptive, candidly discusses how his regenerative therapy start-up evolved and secured start-up funding.

Luis Alvarez, PhD, is the founder of Theradaptive, a biotech start-up focused on regenerative medicines. In this candid discussion with Grant Playter, associate editor, Luis discusses his company’s regenerative bone therapy, how it evolved from his experiences in Iraq, how Theradaptive secured funding in a lukewarm venture capital market, and more.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 22nd 2025

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

Susan Haigney
The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.
Drug Solutions Podcast: Examining the State of Biopharma Investment
June 6th 2023

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com
April 25th 2025

CN Bio Forms Strategic Partnership with Pharmaron to Develop OOC Technologies

Feliza Mirasol
Under the partnership, Pharmaron will validate and promote the application of CN Bio’s PhysioMimix technology and will integrate OOC technologies into its R&D platform.
Blue Paper Boat Leading A Fleet Of Small White Boats With Compass Icon On Grey Concrete - Leadership Concept | Image Credit: ©Philip Steury -stock.adobe.com
April 8th 2025

Navigating the Complexities of Emerging Therapy Development

Cynthia A. Challener
Advancement of emerging therapies faces hurdles across all aspects and phases of drug development and manufacturing.
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com
April 1st 2025

Facing the Latest Patent Cliff

Mike Hennessy Jr.
Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
March 27th 2025

Novartis’ Steady Investments in Slovenia Result in New Viral Vector Manufacturing Facility and a Growing Work Force

Feliza Mirasol
With a completed €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in R&D that has led to the growth of Slovenia’s workforce.